Plural Carboxamide Groups Or Plural C=o Groups Bonded Directly To The Same Nitrogen Patents (Class 514/616)
  • Patent number: 10287309
    Abstract: The present invention relates to a disaccharide intermediate and a synthesis method thereof, relates to the chemical pharmaceutical field, and more specifically relates to a method for preparing a disaccharide segment of a key intermediate for chemically synthesizing heparin and heparinoid compounds. Disclosed are a new disaccharide intermediate and three methods for synthesizing the disaccharide intermediate, that is, compounds of a formula (4) and glucopyranose protected by different anomeric carbon are made to react in the presence of an active agent, to obtain the disaccharide intermediate. According to the technical solutions of the present invention, synthetic raw materials are easy to obtain, have a mild reaction condition, and are suitable for industrialized production.
    Type: Grant
    Filed: April 28, 2014
    Date of Patent: May 14, 2019
    Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Yanghui Guo, Junhui Zhou, Qingfeng Cai, Hegeng Wei, Hua Bai, Fei Long, Yue Zhang, Yingqiu Wu
  • Patent number: 10001485
    Abstract: The disclosure provides methods for determining the self-renewal potential of a cancer stem cell (CSC), or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC. In alternative embodiments, the disclosure provides methods for determining whether a CSC in a niche is more pro-apoptotic or more anti-apoptotic in relation to a normal stem cell or a CSC from another niche. In alternative embodiments, the disclosure provides methods for determining the prognosis or malignant potential of a cancer. In alternative embodiments, the disclosure provides methods determining the anti-apoptotic versus a pro-apoptotic potential of a cancer stem cell (CSC).
    Type: Grant
    Filed: November 7, 2012
    Date of Patent: June 19, 2018
    Assignee: The Regents of the University of California
    Inventors: Catriona H. Jamieson, Daniel Goff, Kristen Smith
  • Patent number: 9908851
    Abstract: Disclosed are compounds of formulae: (I) and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, Y, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: March 6, 2018
    Assignees: Duke University, University of North Carolina Chapel Hill
    Inventors: Pei Zhou, Eric J. Toone, Robert A. Nicholas
  • Patent number: 9796664
    Abstract: This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: October 24, 2017
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: James R. Rusche, Norton P. Peet, Allen Hopper
  • Patent number: 9790184
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: October 17, 2017
    Assignees: The Broad Institute, Inc., The General Hospital Corporation
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
  • Patent number: 9790170
    Abstract: The present invention provides a novel method for preparing lacosamide with high chiral purity from D-serine. The method of the present invention can obtain lacosamide with high chiral purity in a high yield through a simple and environmentally-friendly process and thus can be easily applied to mass production.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: October 17, 2017
    Assignee: ST PHARM CO., LTD.
    Inventors: Geun Jho Lim, Sun Ki Chang, Jae Hun Kim, Jong Moon Park
  • Patent number: 9782369
    Abstract: Provided herein is a method for treating pain in a subject without risking hepatotoxicity by administering a pharmaceutical composition containing an acetaminophen dimer compound wherein the phenolic hydroxyl groups of two acetaminophen molecules are linked via an ethylene spacer.
    Type: Grant
    Filed: October 4, 2016
    Date of Patent: October 10, 2017
    Assignee: ORPHOMED, INC.
    Inventor: Nikhilesh Nihala Singh
  • Patent number: 9724317
    Abstract: Embodiments of the invention relate to methods and compositions for treating symptoms related to inflammatory conditions and to methods and compositions for treating inflammatory components of a common cold, utilizing various methods of administration od X-ray contrast media (CM).
    Type: Grant
    Filed: January 22, 2016
    Date of Patent: August 8, 2017
    Assignee: 3E Therapeutics Corporation
    Inventors: Elliott C. Lasser, Kenneth H. Lasser
  • Patent number: 9655870
    Abstract: The present invention comprises homeopathic preparations of compounds, methods for using such preparations and delivery systems for the treatment of disease symptoms through the administration of these homeopathic compositions.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: May 23, 2017
    Assignee: FINDCURE.ORG
    Inventors: Floyd Taub, Neal Koller, Char Tara Albert
  • Patent number: 9617256
    Abstract: Antibacterial compounds of formula (I) are provided: as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: April 11, 2017
    Assignee: Achaogen, Inc.
    Inventors: Heinz E. Moser, Qing Lu, Phillip A. Patten, Dan Wang, Ramesh Kasar, Stephen Kaldor, Brian D. Patterson
  • Patent number: 9604923
    Abstract: The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of Stat3 signaling, Stat3 dimerization, Stat3-DNA binding, Stat5-DNA binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, NSC 74859 (S31-201), NSC 42067, NSC 59263, NSC 75912, NSC 11421, NSC 91529, NSC 263435, and pharmaceutically acceptable salts and analogs of the foregoing. Other non-malignant diseases characterized by proliferation of cells that may be treated using the compounds of the invention, but are not limited to, cirrhosis of the liver; graft rejection; restenosis; and disorders characterized by a proliferation of T cells such as autoimmune diseases, e.g., type 1 diabetes, lupus and multiple sclerosis.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: March 28, 2017
    Assignees: H.LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC., UNIVERSITY OF SOUTH FLORIDA, UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: James Turkson, Said M. Sebti, Wayne Guida, Man Lun Yip, Nicholas Lawrence, Harshani Rithma Lawrence, Benjamin Greedy
  • Patent number: 9539305
    Abstract: New improved formulations comprising a first composition and a second composition, the first composition being a streptogramin, the second composition being an inhibitor of lipid A deacetylase resulting in permeabilization of an outer membrane of a microorganism to which it is provided to. Said composition, alone or in combination may be used to treat bacterial infections, providing better efficacy, bioavailability and or pharmacokinetics as compared with other antimicrobial agents. The combination may be provided independently or together, and via any route(s) and in any formulation or form.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: January 10, 2017
    Assignee: FLEURIR ABX LLC
    Inventor: John Lee Pace
  • Patent number: 9480665
    Abstract: Provided herein are methods for treating pain such as acute or chronic pain or fever in subject without risking hepatotoxicity. The subject may be at risk of hepatotoxicity if administrated an acetaminophen monomer. The method includes administering a pharmaceutical composition containing an acetaminophen dimer compound, wherein the phenolic hydroxyl groups of two acetaminophen compounds are linked via an ethylene spacer.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: November 1, 2016
    Assignee: ORPHOMED, INC.
    Inventor: Nikhilesh Nihala Singh
  • Patent number: 9475759
    Abstract: Provided are a Tigecycline crystalline hydrate, and a preparation method therefor and use thereof. The crystalline hydrate has high stability for storage, and is used for the manufacture of a medicament for treating or preventing the infection of respiratory system, hepatobiliary system, facial features, urogenital system, bone and joint, skin and soft tissue and endocarditis, septicemia, meningitis caused by susceptible strains of Gram-positive or Gram-negative bacteria, anaerobic bacteria, chlamydia, and mycoplasma in human or animal.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: October 25, 2016
    Inventor: Lifang Hu
  • Patent number: 9458174
    Abstract: The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumor-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents, and their use as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: October 4, 2016
    Assignee: Stemergie Biotechnology SA
    Inventors: Virginie Clement-Schatlo, Thomas Fessard, Damien Barbaras, Joana Matos, Erick Carreira
  • Patent number: 9452973
    Abstract: Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: September 27, 2016
    Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
    Inventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Catherine Chen, Noel Southall, Wei Zheng, Alexander Agoulnik, Irina Agoulnik
  • Patent number: 9433212
    Abstract: Provided is a novel plant growth regulator. The disclosed plant growth regulator comprises flubendiamide as an active ingredient.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: September 6, 2016
    Assignee: NIHON NOHYAKU CO., LTD.
    Inventors: Nao Tokubuchi, Shingo Tamura, Takao Aoki, Ken Kuriyama
  • Patent number: 9402818
    Abstract: A therapy for renal diseases, in particular renal diseases, which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, palmitoylethanolamide and diethanolamide of fumaric acid are used in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: August 2, 2016
    Assignee: Epitech Group S.r.l.
    Inventors: Francesco Della Valle, Raffaele Migliaccio, Maria Federica Della Valle
  • Patent number: 9365504
    Abstract: Salts of kukoamine B, their preparation method and their pharmaceutical use in preparation of drugs for preventing and treating sepsis. Experiments indicate that salts of kukoamine B have a good effect on antagonizing the key factors inducing sepsis, and can be used in the preparation of drugs for preventing and treating sepsis. Under the current circumstances of the lack of effective measures for the treatment of sepsis in clinical practice, the medicinal formulations, which comprise the salts of kukoamine B, pharmaceutically acceptable carrier and/or diluent, provide a new approach for the prevention and treatment of sepsis.
    Type: Grant
    Filed: March 21, 2011
    Date of Patent: June 14, 2016
    Assignees: THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY UNIVERSITY, PLA, TIANJIN CHASESUN PHARMACEUTICAL CO., LTD.
    Inventors: Jiang Zheng, Xinchuan Zheng, Xin Liu, Hong Zhou, Ning Wang, Hongwei Cao, Yan Li, Yongling Lu, Kecen Zhao, Jingcheng Yang, Yang Yang, Yuanfeng Zhu, Guo Wei, Min Huang
  • Patent number: 9309256
    Abstract: Pharmaceutically active homo-dimers of opioid and other pharmaceutically active agents characterized by a single phenolic hydroxyl group wherein the respective monomers are ether-linked through such groups by an ethylene residue. The dimers share the receptor pharmacology of the corresponding monomer, in particular cases are non-absorbed, and the ether link of the dimers is particularly resistant to metabolism when administered to a subject, all conferring divers advantages relative to the corresponding monomers. Exemplary of the dimers are those of buprenorphine, naloxone, naltrexone, des-venlafaxine, albuterol and acetaminophen.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: April 12, 2016
    Assignee: OrphoMed, Inc.
    Inventor: Nikhilesh Nihala Singh
  • Patent number: 9266822
    Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Form B, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Form B, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 23, 2016
    Assignee: THE BROAD INSTITUTE, INC.
    Inventors: Edward Holson, Florence F. Wagner, G. Patrick Stahly
  • Patent number: 9115090
    Abstract: Zn2+-chelating motif-tethered fatty acids as histone deacetylase (HDAC) inhibitors. Compounds performed well in in vitro and in vivo tests.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: August 25, 2015
    Assignee: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventor: Ching-Shih Chen
  • Publication number: 20150148899
    Abstract: A scleral lens is provided with a sodium channel blocker or a sodium channel modulator disposed in the pre-corneal tear film between the scleral lens and the cornea. This system can be used to deliver sodium channel blockers or a sodium channel modulators not currently used because of poor bioavailability. Methods of using this sodium channel blocker delivery system or a sodium channel modulator delivery system are also disclosed.
    Type: Application
    Filed: February 2, 2015
    Publication date: May 28, 2015
    Inventor: Perry ROSENTHAL
  • Publication number: 20150148423
    Abstract: This disclosure describes methods of use for N-acetylcysteine amide for the treatment of various disorders
    Type: Application
    Filed: April 26, 2013
    Publication date: May 28, 2015
    Applicant: SENTIENT LIFESCIENCES, INC.
    Inventor: Glenn A. Goldstein
  • Publication number: 20150141470
    Abstract: A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a MAPK pathway inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and a GEF or HDAC inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a MAPK inhibitor, such as a RAF inhibitor, MEK inhibitor, or ERK inhibitor, and an effective amount of a GEF or HDAC inhibitor. A method of identifying targets that confers resistance to a MAPK pathway inhibitor is also provided.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 21, 2015
    Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Levi A. Garraway, Cory M. Johannessen
  • Publication number: 20150133558
    Abstract: This disclosure describes methods of use for N-acetylcysteine amide for the treatment of penetrating head injury.
    Type: Application
    Filed: October 15, 2014
    Publication date: May 14, 2015
    Inventor: Glenn A. Goldstein
  • Publication number: 20150133465
    Abstract: The invention provides compounds of formula (I): wherein R1-R3, n, and W have any of the values defined in the specification, and salts thereof. The compounds have good solubility and are useful for treating bacterial infections.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Inventors: Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Yongzheng Zhang, Malvika Kaul
  • Patent number: 9023893
    Abstract: The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: May 5, 2015
    Assignee: Novartis AG
    Inventors: William Hewitt, Daniel L Vasella, Randy L Webb
  • Patent number: 9023894
    Abstract: The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: May 5, 2015
    Assignee: Novartis AG
    Inventors: William Hewitt, Daniel L Vasella, Randy L Webb
  • Patent number: 9023836
    Abstract: The present invention relates to the use of compounds of formula wherein the variables are as defined in the description, in the free form or in salt form, for controlling sea lice on fish.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: May 5, 2015
    Assignee: Novartis Tiergesundheit AG
    Inventors: Jean-Luc Perret, David Blaser, Steve Nanchen
  • Publication number: 20150119426
    Abstract: Disclosed are modulators of the human relaxin receptor 1, for example, of formula (I), wherein A, R1, and R2 are as defined herein, that are useful in treating mammalian relaxin receptor 1 mediated facets of human health, e.g., cardiovascular disease. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the disclosure, and a method for therapeutic intervention in a facet of mammalian health that is mediated by a human relaxin receptor 1.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 30, 2015
    Inventors: Juan Jose Marugan, Jingbo Xiao, Marc Ferrer-Alegre, Catherine Chen, Noel Southall, Wei Zheng, Alexander Agoulnik, Irina Agoulnik
  • Publication number: 20150119423
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of local pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of moderate to severe pain, neuropathic pain, post herpetic neuralgia and rheumatic pains.
    Type: Application
    Filed: May 18, 2013
    Publication date: April 30, 2015
    Inventor: Mahesh Kandula
  • Publication number: 20150104507
    Abstract: A modified release formulation of lacosamide.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 16, 2015
    Inventors: Willi CAWELLO, Martin Alexander SCHUBERT
  • Publication number: 20150094294
    Abstract: The present disclosure provides compounds, specifically pyrimidin-4,6-dicarboxylic acid amide derivatives, or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing said compounds. Also provided are methods for treating a mammal having malaria, or killing or inhibiting the growth of a Plasmodium species, comprising administering to said mammal or contacting said Plasmodium species with, an effective amount of a pyrimidin-4,6-dicarboxylic acid amide derivative.
    Type: Application
    Filed: February 28, 2013
    Publication date: April 2, 2015
    Inventors: Richard W. Scott, Robert W. Kavash, Wenxi Pan, Katie Freeman, Michael J. Costanzo, Doron Greenbaum, Yongjiang Xu, Trevor Young
  • Publication number: 20150080472
    Abstract: The invention provides methods of treating Friedreich's ataxia using histone deacetylase inhibitors.
    Type: Application
    Filed: September 9, 2014
    Publication date: March 19, 2015
    Inventors: JOEL M. GOTTESFELD, ANN-KRISTIN JENSSEN, DAVID M. HERMAN, RYAN BURNETT, C. JAMES CHOU
  • Publication number: 20150080439
    Abstract: Various embodiments of the present invention relate to, among other things, compounds that are inhibitors of Memapsin 1 and, as a result, are effective in the treatment of Alzheimer's disease or diabetes (e.g., Type 2 diabetes).
    Type: Application
    Filed: September 12, 2014
    Publication date: March 19, 2015
    Inventor: Arun K. Ghosh
  • Patent number: 8981149
    Abstract: The invention relates to compounds of formula (I), and the use thereof as a drug, particularly for the treatment of tumors associated with hyperactivation of the hedgehog protein signaling pathway, treatment of neurodegenerative diseases, treatment of diseases related to cerebral development (holoprosencephaly), for stem cell monitoring treatment of cerebrovascular accidents and cardiovascular accidents, treatment of diseases involving oligodendrocytes and diseases involving neurolemmocytes, for application thereof in vitro for modulating human or animal stem cell renewal, and for the treatment of diabetes. The invention also relates to pharmaceutical compositions having a compound of formula (I).
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: March 17, 2015
    Assignees: Centre National de la Recherche Scientifique, Universite de Strasbourg
    Inventors: Martial Ruat, Hélène Faure, Hermine Roudaut, Lucile Hoch, Angèle Schoenfelder, Maurizio Taddei, André Mann
  • Publication number: 20150065508
    Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
    Type: Application
    Filed: March 26, 2014
    Publication date: March 5, 2015
    Applicant: ABBVIE INC.
    Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Vince S. Yeh
  • Publication number: 20150065497
    Abstract: Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
    Type: Application
    Filed: August 5, 2014
    Publication date: March 5, 2015
    Inventors: Sara S. Hadida Ruah, Mark T. Miller, Brian Bear, Jason McCartney, Peter D.J. Grootenhuis
  • Publication number: 20150065576
    Abstract: A therapy for renal diseases, in particular renal diseases, which develop in diabetic patients or patients who have been subjected to a treatment with an antitumor chemotherapy such as a platinum derivative and more generally cytotoxic drugs at renal level for treating of neoplastic diseases. More particularly, palmitoylethanolamide and diethanolamide of fumaric acid are used in the treatment of renal diseases, in particular those caused by dysmetabolic diseases or by toxic or chemotherapy agents, such as platinum derivatives. Palmitoylethanolamide is used preferably in micronized or ultra-micronized form. Diethanolamide of fumaric acid is used preferably in aqueous solution.
    Type: Application
    Filed: November 7, 2014
    Publication date: March 5, 2015
    Inventors: Francesco Della Valle, Raffaele Migliaccio, Maria Federica Della Valle
  • Publication number: 20150056305
    Abstract: Provided are dithiol mucolytic agents. These agents increase the liquefaction of mucus in a patient with excessive mucus or mucus with increased viscoelastic, cohesive, or adhesive properties. Also provided are a variety of methods of treatment using these inventive mucolytic agents.
    Type: Application
    Filed: August 13, 2014
    Publication date: February 26, 2015
    Applicant: PARION SCIENCES, INC.
    Inventors: Michael R. Johnson, William R. Thelin, Ronald A. Aungst, JR.
  • Patent number: 8962690
    Abstract: A biocidal composition comprising 2,2-dibromomalonamide and a surface active biocide, and its use for the control of microorganisms in aqueous and water-containing systems.
    Type: Grant
    Filed: September 27, 2010
    Date of Patent: February 24, 2015
    Assignee: Dow Global Technologies LLC
    Inventors: Bei Yin, Freddie L. Singleton
  • Patent number: 8962546
    Abstract: This application provides methods of increasing vascularization, muscle performance, muscle rehabilitation, and/or mitochondrial activity in subjects in need thereof, by administering a therapeutically effective amount of one or more agents that increases ERR? activity to the subject. Such agents can include one or more ERR? agonists. In some examples the method does not require that the subject exercise, and as such, the subject may be sedentary (such as bedridden or in a wheelchair).
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: February 24, 2015
    Assignee: Salk Institute for Biological Studies
    Inventors: Vihang A. Narkar, Michael Downes, Ruth T. Yu, Ronald M. Evans
  • Publication number: 20150045367
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Application
    Filed: December 19, 2012
    Publication date: February 12, 2015
    Inventors: Erik Verner, Wei Chen, Sriram Balasubramanian
  • Publication number: 20150038512
    Abstract: Compounds, compositions, and methods comprising a polyamine compound are described, which may be used to kill, disperse, treat, or reduce biofilms, or to inhibit or substantially prevent biofilm formation. In certain aspects, the present invention relates to compounds, compositions, and methods comprising polyamine compounds that have antimicrobial or dispersing activity against a variety of bacterial strains capable of forming biofilms.
    Type: Application
    Filed: October 6, 2014
    Publication date: February 5, 2015
    Inventors: Ryan Looper, Dustin Williams, Sujeevini Jeyapalina, Travis Haussener, Paul R. Sebahar, Hariprasada R. Kanna Reddy
  • Publication number: 20150038586
    Abstract: This disclosure describes methods of use for N-acetylcysteine amide for the treatment of penetrating head injury.
    Type: Application
    Filed: July 10, 2014
    Publication date: February 5, 2015
    Inventor: Glenn A. Goldstein
  • Patent number: 8946477
    Abstract: The invention relates to solid forms of the anti-epileptic agent lacosamide (I). The invention also relates to mixtures of solid forms of lacosamide. The invention further relates to mixtures of lacosamide enantiomers crystallized in a conglomerate Form and the use thereof in providing enantiomerically enriched lacosamide, preferably lacosamide enriched with the (R)-enantiomer of lacosamide.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: February 3, 2015
    Assignee: Medichem, S.A.
    Inventors: Ernesto Duran Lopez, Monica Benito Velez, Jordi Bosch i Lladó
  • Publication number: 20150030669
    Abstract: The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Optionally one or more further bioactive agents may be encapsulated or embedded within or attached to or adsorbed onto the carrier system. The present invention is further directed to methods of their preparation and their uses in medical applications, such as targeted delivery of bioactive agents to specific tissues or cells and antigen display systems for the study, diagnosis, and treatment of traits, diseases and conditions that respond to said bioactive agents.
    Type: Application
    Filed: March 11, 2013
    Publication date: January 29, 2015
    Applicant: MERCK PATENT GMBH
    Inventors: Michael Wilhelm Platscher, Raymond Behrendt, Viola Groehn, Simone Rachel Hoertner, Marco Silvio Passafaro, Finn Bauer
  • Publication number: 20150023868
    Abstract: The present invention is directed to HIF inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.
    Type: Application
    Filed: February 21, 2014
    Publication date: January 22, 2015
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Othon Iliopoulos, Michael Zimmer
  • Patent number: 8933065
    Abstract: A first aspect of the invention is a compound (sometimes also referred to herein as an “active agent” or “active compound”) of Formula I or Ia: or a pharmaceutically acceptable salt or prodrug thereof. Compositions thereof and methods of using the same (e.g. for the treatment of a neurological disease) are also described.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: January 13, 2015
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Harold L. Kohn, Christophe Salomé, Ki Duk Park, Elise Salomé-Grosjean